Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Ipsen SA

IPN.PA ✓ COMPLIANT ☆ Track — members

Euronext Paris · Healthcare · Pharmaceuticals ·

France Large Cap Analyst: HOLD

Last Close

$180.48

▼ -0.95%

Market Cap $15.07B · Vol 79.67K

Key Metrics

P/E Ratio

25.26

FWD: 11.38

Market Cap

$15.07B

Large Cap

Div Yield

1.03%

Annual dividend

EPS Growth

+12.85%

YoY

RSI (14)

47.52

Momentum

Beta

0.44

vs Market

52W High

$201.30

11.45% below

52W Low

$127.14

40.35% above

Volume

79.67K

Avg 111.70K

P/B

2.26

Price-to-book

ROE

23.67%

Return on equity

Free Float

41.36%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Ipsen SA (IPN.PA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IPN.PA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.47%

-1.52%

-5.91%

+0.84%

YTD

+31.09%

+40.16%

+35.11%

+93.79%

Financials & Valuation

TTM · Annual

Total Revenue	$4.61B
Net Income	$522.89M
Revenue Growth (YoY)	+18.69%
Gross Margin	74.16%
Operating Margin	24.51%
Net Profit Margin	11.31%
ROE	23.67%
ROA · ROIC	8.65% · 9.43%

P/E Ratio	25.26
Forward P/E (FY1)	11.38
PEG Ratio	0.91
P/S	2.53
P/B	2.26
P/FCF	12.17
EPS Growth	+12.85%
Outstanding Shares	83.81M

Technical Indicators

50-Day SMA	$186.08
200-Day SMA	$171.92
RSI (14)	47.52
Beta	0.44
52-Week High	$201.30
52-Week Low	$127.14

Volume Today	79.67K
Avg Daily Volume (30D)	111.70K
Relative Volume	0.71x
Volatility (10D)	48.50
Volatility (30D)	40.52
Free Float	41.36%

Analyst Consensus

HOLD

Current Price $180.48

Mean Target $192.19

52W Low$127.14 52W High$201.30

Current

Target

$127.14 $201.30

Current Analyst target

+6.49% upside potential · 16 analysts

Identifiers

ExchangeEuronext Paris

FIGIBBG001SFCJ35

ISINFR0010259150

CountryFrance

Sub-IndustryPharmaceuticals (NEC)

Earnings DateFeb 10, 2027

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.